Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics

Akintunde Akinleye; Parthu Avvaru; Muhammad Furqan; Yongping Song; Delong Liu

doi:10.1186/1756-8722-6-88

Back

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics

Journal article

Open access

Peer reviewed

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics

Akintunde Akinleye, Parthu Avvaru, Muhammad Furqan, Yongping Song and Delong Liu

Journal of hematology and oncology, Vol.6(1), pp.88-88

11/22/2013

DOI: 10.1186/1756-8722-6-88

PMCID: PMC3843585

PMID: 24261963

Files and links (1)

url

https://doi.org/10.1186/1756-8722-6-88View

Published (Version of record) Open Access

Abstract

Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that regulate diverse cellular processes including proliferation, adhesion, survival, and motility. Dysregulated PI3K pathway signaling occurs in one-third of human tumors. Aberrantly activated PI3K signaling also confers sensitivity and resistance to conventional therapies. PI3K has been recognized as an attractive molecular target for novel anti-cancer molecules. In the last few years, several classes of potent and selective small molecule PI3K inhibitors have been developed, and at least fifteen compounds have progressed into clinical trials as new anticancer drugs. Among these, idelalisib has advanced to phase III trials in patients with advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. In this review, we summarized the major molecules of PI3K signaling pathway, and discussed the preclinical models and clinical trials of potent small-molecule PI3K inhibitors.

Review

Details

Title: Subtitle: Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Creators: Akintunde Akinleye - Division of Hematology/Oncology, Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
Parthu Avvaru - Division of Hematology/Oncology, Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
Muhammad Furqan - Division of Hematology/Oncology, Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
Yongping Song - Henan Cancer Hospital, Zhengzhou University, Zhengzhou, China
Delong Liu - Division of Hematology/Oncology, Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
Resource Type: Journal article
Publication Details: Journal of hematology and oncology, Vol.6(1), pp.88-88
DOI: 10.1186/1756-8722-6-88
PMID: 24261963
PMCID: PMC3843585
NLM abbreviation: J Hematol Oncol
ISSN: 1756-8722
eISSN: 1756-8722
Publisher: BioMed Central
Language: English
Date published: 11/22/2013
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984094332602771

Metrics

23 Record Views

224 Times Cited - Web of Science